Skip to content
Biotech Intelligence

Pfizer

pharmaNew York
Trials
0
Subs
0
People
0
Links
11

Executive Summary

AI synthesis

This appears to be incomplete or erroneous data - Pfizer is a major US pharmaceutical company headquartered in New York, not a Chinese entity. Pfizer has no BIOSECURE risk as it's an American multinational corporation. If evaluating the actual Pfizer Inc., they would be a potential partner rather than acquisition target, with strong pipeline capabilities across oncology, vaccines, and rare diseases.

Structure: Data inconsistency detected - Pfizer Inc. is a US publicly traded company (NYSE: PFE) with standard Delaware corporation structure. If this refers to a different Chinese entity with similar naming, corporate structure details are not available in the provided data.

Ownership & Shareholder Structure

—

3SBio → Pfizer

deal_partner

Pfizer-3SBio $4.8B bispecific antibody ($1.25B upfront).

—

Zai Lab → Pfizer

personnel

Samantha Du (Zai Lab founder) was former VP at Pfizer.

—

Hutchmed → Pfizer

personnel

Weiguo Su (HUTCHMED CEO) was former VP at Pfizer.

—

CStone Pharmaceuticals → Pfizer

deal_partner

CStone-Pfizer sugemalimab collaboration for oncology in China.

—

Insilico Medicine → Pfizer

deal_partner

Insilico AI drug discovery collaboration with Pfizer.

—

Simcere Pharmaceutical → Pfizer

deal_partner

Simcere licensed Pfizer products for China distribution.

—

WuXi AppTec → Pfizer

cdmo_client

WuXi AppTec provides CDMO services to Pfizer. Key API manufacturing relationship.

—

Asymchem Laboratories → Pfizer

cdmo_client

Asymchem manufactured Paxlovid API for Pfizer. Key CDMO relationship.

—

Tigermed → Pfizer

cdmo_client

Tigermed provides CRO services to Pfizer for China clinical trials.

—

Pharmaron → Pfizer

cdmo_client

Pharmaron provides drug discovery CRO services to Pfizer.

—

Porton Pharma Solutions → Pfizer

cdmo_client

Porton provides intermediate manufacturing to Pfizer.

BIOSECURE Risk

low

If referring to US Pfizer Inc., no BIOSECURE risk as it's an American company. If referring to a Chinese entity, insufficient data to assess risk properly.

Mitigation: Not applicable for US Pfizer Inc.

BD Intelligence

Pipeline Strength0/10
Deal Readiness0/10

Therapeutic Areas:

Recent Deals: No data available - entity information appears incomplete or incorrect

Approach: Clarify entity identity before proceeding - data suggests confusion between US Pfizer Inc. and unknown Chinese entity

Red Flags

  • ⚠Entity data inconsistency - Chinese company classification with US pharma giant name
  • ⚠No key personnel data available
  • ⚠No subsidiary information provided
  • ⚠No recent corporate events recorded
  • ⚠Missing ticker symbol despite apparent public company status

Quick Facts

Key People
0
Subsidiaries
0
CDMO/CRO Subs
0
Genomics Subs
0
Direct BIOSECURE
0
Corp Events
0
Gov-Connected
0
Clinical Trials
0
Publications
0
Drug Molecules
0
Relationships
11

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (0 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.